#United States #Northbrook #Kalohexis #MC3R/MC4R #ICO 2026

A Transformative Approach to Obesity Treatment

At the upcoming International Congress on Obesity (ICO 2026) in Mexico City, Kalohexis, Inc., a leading clinical-stage biotechnology firm, is making waves with compelling new research. The company has introduced an innovative strategy for treating obesity, utilizing the dual activation of melanocortin-3 receptor (MC3R) and melanocortin-4 receptor (MC4R). This cutting-edge approach appears to facilitate significant weight loss while minimizing the risk of rebound and preserving lean muscle mass in obese nonhuman primates.

The Significance of MC3R/MC4R Activation

Research has shown that the melanocortin system plays a crucial role in regulating energy balance and metabolism. By simultaneously activating both the MC3R and MC4R, Kalohexis aims to leverage the body’s natural mechanisms to drive weight loss more effectively than traditional methods. This novel mechanism, showcased at ICO 2026, highlights Kalohexis’ commitment to pioneering metabolic disease therapies.

Presentation Details at ICO 2026

During the conference, Kalohexis will present a poster titled, "Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman Primates." The presentation falls under the Basic Science track and focuses on advances in pharmacotherapy for obesity. The dates for the presentation are set from July 15 to July 17, 2026.

Overview of Kalohexis' Research Findings

In previous studies, particularly at ENDO 2026, data indicated that Kalohexis’ oral dual MC3R/MC4R agonist, known as 710GO, is currently undergoing Phase 1 clinical trials. The findings suggest that this agent not only promotes weight loss but also enhances the quality of that weight loss by limiting the rebound effect—the tendency to regain weight after losing it.

The significance of this research is underlined by the fact that obesity is a burgeoning global public health issue, affecting millions worldwide. Kalohexis aims to address these challenges by developing treatments that enhance long-term outcomes and improve the quality of life for individuals affected by metabolic disorders.

Kalohexis: Company Overview

Founded in March 2026 and spun out of Endevica Bio, Kalohexis is dedicated to revolutionizing metabolic disease care. Beyond its research into obesity treatment, the company is working on therapeutic peptide candidates targeting MC3R/MC4R to treat various metabolic disorders, including cachexia in cancer patients.

The potential of Kalohexis’ programs, such as 710GO, signals a promising future for treating obesity with better efficacy and sustainability in mind. As the company continues to advance its research, their commitment to innovation in obesity and metabolic disease management remains clear.

The Future of Metabolic Treatments

The presentation at ICO 2026 is not just another academic endeavor; it could herald a new era in the fight against obesity and related conditions. Kalohexis’ findings could pave the way for effective interventions that fundamentally change how we approach metabolic disease therapies.

For further information on Kalohexis Inc. and its promising therapeutic programs, interested parties can visit www.kalohexis.com to stay updated on their latest developments and breakthroughs in metabolic disease treatment.